Hemab Therapeutics Holdings, Inc. Common Stock COAG
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $51.40 (+62.6% upside)
Key Stats
- Today's Range
- $29.98 – $33.93
- 50-Day Range
- $27.38 – $55.42
- 52-Week Range
- $23.00 – $55.42
- Volume
- 619K shs
- Average Volume
- 552K shs
- Market Cap
- $1.44 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.62%
- Days to Cover
- 1.22
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Related Stocks
Compare head-to-head: COAG vs AMGN·COAG vs MRNA·COAG vs HALO·COAG vs TWST
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.